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Systematic review of long term anticoagulation or
antiplatelet treatment in patients with non›rheumatic atrial
fibrillation
F C Taylor, H Cohen, S Ebrahim
Abstract
Objective To examine the benefits and risks of long
term anticoagulation (warfarin) compared with
antiplatelet treatment (aspirin/indoprofen) in patients
with non›rheumatic atrial fibrillation.
Methods Meta›analysis of randomised controlled
trials from Cochrane library, Medline, Embase, Cinhal,
and Sigle from 1966 to December 1999. Odds ratios
(95% confidence intervals) calculated to estimate
treatment effects.
Outcome measures Fatal and non›fatal
cardiovascular events, reductions of which were
classified as benefits. Fatal and major non›fatal
bleeding events classified as risks.
Results No trials were found from before 1989. There
were five randomised controlled trials published
between 1989›99. There were no significant
differences in mortality between the two treatment
options (fixed effects model: odd ratio 0.74 (95%
confidence interval 0.39 to 1.40) for stroke deaths;
0.86 (0.63 to 1.17) for vascular deaths). There was a
borderline significant difference in non›fatal stroke in
favour of anticoagulation (0.68 (0.46 to 0.99)); and
0.75 (0.50 to 1.13) after exclusion of one trial with
weak methodological design. A random effects model
showed no significant difference in combined fatal
and non›fatal events (odds ratio 0.79 (0.61 to 1.02)).
There were more major bleeding events among
patients on anticoagulation than on antiplatelet
treatment (odds ratio 1.45 (0.93 to 2.27)). One trial
was stopped prematurely after a significant difference
in favour of anticoagulation was observed. The only
trial to show a significant difference in effect
(favouring anticoagulation) was methodologically
weaker in design than the others.
Conclusions The heterogeneity between the trials
and the limited data result in considerable uncertainty
about the value of long term anticoagulation
compared with antiplatelet treatment. The risks of
bleeding and the higher cost of anticoagulation make
it an even less convincing treatment option.
Introduction
In the past decade there has been widespread
implementation of oral anticoagulation (warfarin) in
preference to antiplatelet treatment (aspirin/
indoprofen) to reduce the risk of cardiovascular
mortality and morbidity in patients with non›
rheumatic atrial fibrillation.1 This choice of treatment
has been based on evidence from randomised control
trials that compared long term anticoagulation with
placebo and antiplatelet treatment with placebo.
Reviews pooling efficacy estimates of such trials for
anticoagulation have shown considerable benefits, with
an odds reduction for non›fatal stroke of 68% with low
rates of bleeding.2–4 Pooled efficacy estimates for
antiplatelet treatment have shown less benefit. The
combined fatal and non›fatal vascular event rates were
10.8% for aspirin versus 13.5% for placebo, a 28%
reduction in risk.5 6 From these reviews it might be
concluded that long term anticoagulation results in
substantially greater benefits in non›rheumatic atrial
fibrillation, indeed more than twice as great a relative
effect on treatment. To make this judgment, however,
direct head to head comparison of the effects of long
term anticoagulation and antiplatelet drugs in compa›
rable patients is necessary. Indirect comparisons of the
effects of the two treatment options may be biased by
different selection criteria used in trials, leading to dif›
ferences in prognosis unrelated to treatment and over›
estimation of treatment effects.7 We undertook a
systematic review of evidence from randomised
controlled trials to determine unbiased estimates of
which is the better treatment option.
Methods
We conducted a literature search, following established
guidelines,8 9 using the Cochrane CENTRAL database,
Embase, Medline, Cinhal, and Sigle for grey literature
from 1966 to December 1999. We used the terms
atherosclerosis or atrial fibrillation or myocardial
infarction or coronary disease and anticoagulation and
a randomised control trial filter.10 We cross referenced
from papers obtained from the database search and
approached key authors for advice on missed, unpub›
lished, and ongoing trials. Inclusion criteria were trials
of patients with non›rheumatic atrial fibrillation
randomised to either long term anticoagulation (one
year or more) or antiplatelet treatment. We excluded
randomised control trials that evaluated combined use
of anticoagulation with antiplatelet drugs and trials
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that included patients with atrial fibrillation due to thy›
rotoxicosis and mitral valve disease and patients with
heart valve replacements.
Outcome measures abstracted from the papers
were fatal and non›fatal cardiovascular events (that is,
stroke, myocardial infarction, and thromboembolism),
reductions of which were classified as benefits.
Non›fatal cardiovascular disease events were not
always documented well enough to permit analysis of
their severity and their long term effects. Major bleed›
ing events were classified as risks and comprised fatal
and non›fatal bleeding events that required hospital
admission. Lack of detailed information on bleeding
precluded any categorisation by severity of bleeding.
Quality of trials was assessed from the level of conceal›
ment of random allocation, degree of blinding used,
and losses to follow up. We considered the relation
between each criterion of quality and outcomes
separately.
Statistical analysis
We used dichotomous variables that reflected each
outcome. Analysis was confined to intention to treat
principles in which all patients randomised were
included. Pooled effect estimates and heterogeneity
between studies were tested with REVMAN 3.1 statisti›
cal package.11 When heterogeneity was significant with
the fixed effects model we used a random effects
model. We calculated odds ratios and 95% confidence
intervals to estimate treatment effects. We used STATA
to assess funnel plot asymmetry (to investigate
publication bias)12 with both Begg’s13 and Egger’s14
methods and for meta›regression analysis.
Results
We identified five relevant randomised controlled
trials, which were published in 1989›99 (table 1).15–19
One trial used age stratified randomisation and the fol›
low up of patients was longer for the younger age
group compared with the older age group.17 We
considered this as two trials for the purpose of this
review. Two of the trials examined the effects of fixed
low dose warfarin,16 19 but these trial arms were not rel›
evant to our study. Some of the patients included in the
trials were at high risk of a cardiovascular event
because of previous cardiovascular disease. A total of
3298 patients were randomised. There were 82 fatal
vascular events in the anticoagulation group and 95 in
the antiplatelet group (table 2). Individual trial sizes
were small, with the largest recruiting 916 patients, and
the mean follow up period ranged from 12›42 months.
Two trials (AFASAK 1 and 2) were stopped
prematurely. AFASAK 1 was stopped early because of
a significant treatment effect favouring warfarin after
the fourth out of five planned interim analyses of
thromboembolic complications when only half the
planned number had been recruited. AFASAK 2 was
stopped early because the results of another trial indi›
cated that low intensity warfarin plus aspirin was
significantly less effective than adjusted warfarin.15 16
The pooled odds ratios from the fixed effects
model showed non›significant trends in favour of
anticoagulation in deaths from stroke (odds ratio 0.74;
95% confidence interval 0.39 to 1.46) and vascular
death (0.86; 0.63 to 1.17) (table 3). When we used a
random effects model because of heterogeneity
between trials, there was also no significant difference
in the combined fatal and non›fatal events (0.79; 0.61
Table 1 Randomised trials of oral anticoagulants versus antiplatelet treatments in non›rheumatic atrial fibrillation included in
systematic review
Trial Patient characteristics
Intervention
(months of
follow up) INR Random allocation Blinding used
Withdrawals from trial
(warfarin/antiplatelet)
AFASAK 115 Chronic non›rheumatic atrial
fibrillation, no stroke in prevoius
month but 5.5% had previous
TIA/stroke, BP <180/100 mm Hg;
n=671, mean (range) age 73 (38›91)
years
Aspirin 75 mg v
warfarin (24)
2.8›4.2 Drug packages
sequenced randomly by
computer; concealment
of allocation may be
inadequate
Outcomes not
assessed or reviewed
blind to treatment;
statistician blinded
38% (126) v 13% (44)
SPAF II <7517 Non›rheumatic atrial fibrillation >12
months. No TIA/stroke in previous 2
years but 7% had previous
TIA/stroke, n=715, all patients <75,
mean (SD) 64 (8) years
Aspirin 325 mg v
warfarin (36)
2›4.5 Computerised
randomisation
performed in each
centre; concealment
adequate
Outcomes reviewed
blind; not stated for
statistician
Withdrawals not reported
but only 0.8 % (3) v
0.3% (1) lost to follow
up (<0.4% overall)
SPAF II 75+17 As SPAF II <75 but all aged >75
years, n=385, mean (SD) 80 (3) years
Aspirin 325 mg v
warfarin (24)
2.4›4.5 Computerised
randomisation
performed in each
centre; concealment
adequate
Outcomes reviewed
blind; not stated for
statistician
Withdrawals not reported;
no losses to follow up
AFASAK 216 Non›rheumatic atrial fibrillation, third
<1 year duration, 70% diagnosed
heart failure, 8% past TIA/stroke, 8%
history of MI, n=239, mean (SD) age
73 (7) years
Aspirin 300 mg v
warfarin (42)
2.0›3.0 Computerised
randomisation
performed; concealment
adequate
Outcomes reviewed
blind; not stated for
statistician
Overall 16.5% withdrawn
and 8.6% dropped out,
but not broken down by
treatment allocation;
losses to follow up not
reported
SIFA18 Non›rheumatic atrial fibrillation or
paroxysmal AF, 50% had previous
TIA/stroke, n=916, mean (SD) age 73
(8) years
Indoprofen 400
mg v warfarin
(12)
2›3.5 Computerised dial up
telephone randomisation
service; concealment
adequate
Outcomes reviewed
blind; not stated for
statistician
10.6% (48) v 9.1% (42)
PATAF19 Non›rheumatic atrial fibrillation or
paroxysmal AF drawn from primary
care, 9% had history of MI, n=272,
mean (SD) age 75 (7.5) years
Aspirin 150 mg v
warfarin (31)
2.5›3.5 Computerised dial up
telephone randomisation
service; concealment
adequate
Outcomes reviewed
blind; not stated for
statistician
No losses to follow up
INR=international normalised ratio, MI=myocardial infarction, TIA=transient ischaemic attack, AF=atrial fibrillation.
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to 1.02) (table 3, figure). We found no evidence of fun›
nel plot asymmetry. Meta›regression on quality of out›
come in trials (for instance, concealment of randomi›
sation, blinding, losses to follow up) showed no
significant trend.
Only AFASAK 1 reported greater benefits from
long term anticoagulation than antiplatelet treatment,
with a 67% reduction in risk of non›fatal stroke (table
3). These results must be interpreted with caution
because methodological quality of this trial was lower
than in the other trials. It was the only trial in which
outcomes were not assessed or reviewed blind of treat›
ment allocation. Also the concealment of randomisa›
tion was inadequate as the drug packages were
randomly sequenced and matched to patients’
consecutive study numbers and thus could potentially
be distinguished by medical staff. Patients receiving
anticoagulation were significantly older than those
receiving aspirin, suggesting that randomisation had
not provided comparable groups. Lack of blinding and
inadequate concealment of allocation are both associ›
ated with overestimation of treatment effects.20
Furthermore, withdrawals from treatment were higher
than in the other trials and the trial was stopped
prematurely, which may also lead to overestimation of
treatment effects. The dose of aspirin used was small
(75 mg) compared with the dose used in other trials
(table 1). Consequently, this result may skew the
Table 2 Summary of clinical events in trials of oral anticoagulation versus antiplatelet treatment in patients with non›rheumatic atrial fibrillation
Trial No randomised
Fatal outcomes Non›fatal outcomes Other outcomes
Stroke Vascular All causes Stroke TIA Thromboembolic MI
Combined fatal
and non›fatal*
Trial defined
primary outcome Major bleeds
AFASAK 115
Warfarin 335 1 3 † 4 0 0 ¶ 13‡ 5 2§
Aspirin 336 3 12 ¶ 12 2 3 ¶ 30 20 1
SPAF II <7517
Warfarin 357 0 20 36 13 7 1 10 51 14 19
Aspirin 358 2 25 41 17 11 2 14 69 21 10
SPAF II 75+17
Warfarin 197 1 16 26 12 3 1 5 37 14 16
Aspirin 188 2 14 24 16 4 0 5 39 18 6
AFASAK 216
Warfarin 170 0 5 17 10 1 2 3 21 12 6
Aspirin 169 2 4 14 7 2 1 2 16 10 6
SIFA18
Warfarin 454 13 29 32 5 ¶ 5 2 41 41 4
Indoprofen 462 11 31 35 12 ¶ 4 2 49 49 0
PATAF19
Warfarin 131 0 9 12 3 ¶ 3 1 16 10 2
Aspirin 141 1 9 17 4 ¶ 4 2 19 12 11
*Combined fatal and non›fatal outcomes comprise vascular deaths and all non›fatal vascular events.
†No data presented but reported that there were no significant differences in vascular or total mortality in intention to treat analysis.
‡Combined events do not total as six thromboembolic events in warfarin group and one in aspirin group occurred when patients were not taking treatment, which were not included in published
main analyses. $Not all major bleeding events were reported. ¶Not reported.
Table 3 Summary of treatment effects in trials of oral anticoagulation versus antiplatelet treatment in patients with non›rheumatic atrial fibrillation. Figures
are odds ratios (95% confidence intervals)
Trial
Fatal outcomes Non›fatal outcomes Other outcomes
Stroke Vascular All cause Stroke
Myocardial
infarction
Combined fatal
and non›fatal*
Trial defined
primary outcome Major bleeds
AFASAK 115 0.33 (0.03 to 3.2) 0.24 (0.07 to 0.87) Not investigated 0.33 (0.10 to 1.02) Not investigated 0.41 (0.21 to 0.80) 0.24 (0.09 to 0.65) 2.01 (0.18 to 22.30)
SPAF II <7517 0.20 (0.01 to 4.14) 0.79 (0.04 to 1.44) 0.86 (0.53 to 1.38) 0.75 (0.36 to 1.58) 0.70 (0.31 to 1.61) 0.69 (0.47 to 1.03) 0.65 (0.33 to 1.30) 1.94 (0.89 to 4.24)
SPAF II 75+17 0.47 (0.04 to 5.28) 1.10 (0.52 to 2.32) 1.04 (0.57 to 1.88) 0.70 (0.32 to 1.52) 0.95 (0.27 to 3.35) 0.88 (0.53 to 1.46) 0.72 (0.35 to 1.50) 2.68 (1.03 to 7.01)
AFASAK 216 0.20 (0.01 to 4.12) 1.23 (0.33 to 4.74) 1.23 (0.59 to 2.58) 1.45 (0.54 to 3.89) 1.50 (0.25 to 9.09) 1.35 (0.68 to 2.68) 1.21 (0.51 to 2.88) 0.99 (0.31 to 3.14)
SIFA18 1.21 (0.54 to 2.73) 0.92 (0.56 to 1.60) 0.92 (0.56 to 1.52) 0.42 (0.15 to 1.20) 1.02 (0.14 to 7.26) 0.84 (0.54 to 1.29) 0.84 (0.54 to 1.29) 9.24 (0.50 to 172.11)
PATAF19 0.36 (0.01 to 8.82) 1.08 (0.42 to 2.81) 0.74 (0.34 to 1.61) 0.80 (0.18 to 3.66) 0.53 (0.05 to 5.97) 0.89 (0.44 to 1.82) 0.89 (0.37 to 2.13) 0.18 (0.04 to 0.84)
Pooled effects
(95% CI)
0.74 (0.39 to 1.40) 0.86 (0.63 to 1.17) 0.94 (0.72 to 1.21) 0.68 (0.46 to 0.99) 0.83 (0.46 to 1.50) 0.79 (0.61 to 1.02) 0.73 (0.52 to 1.02) 1.45 (0.93 to 2.27)
*Combined fatal and non›fatal outcomes comprises vascular deaths and all non›fatal vascular events.
AFASAK 115
Favours anticoagulation Favours antiplatelets
SPAF II 75+17
SPAF II <7517
AFASAK 216
SIFA18
PATAF19
Overall (95% CI) 63 to 1.17)0.86 (0.
0.1 0.5 1 1.5 3
Odds ratio
0.05
Comparison of fatal vascular outcomes in trials of anticoagulation
versus antiplatelet treatment
Papers
323BMJ VOLUME 322 10 FEBRUARY 2001 bmj.com
combined pooled odds ratio for non›fatal stroke, the
combined fatal and non›fatal events, and the primary
outcome defined in the trial. A sensitivity analysis
excluding AFASAK 1 showed a reduction in
heterogeneity between trials and attenuated non›
significant effects of anticoagulation compared with
antiplatelet treatment in non›fatal stroke (odds ratio
0.75; 0.50 to 1.13) and combined fatal and non›fatal
outcomes (0.84; 0.67 to 1.06).
In all trials, with the exception of AFASAK 2, the
ranges for the international normalised ratio were
higher than the recommended range of 2›3 (table 1).21
However, all trials stated that anticoagulant control was
adequate, and two reported satisfactory patient compli›
ance.18 19 We could not compare the intensity of
anticoagulation because of the varying methods of
monitoring and reporting of therapeutic control within
the trials. Major bleeding events were more common
among those treated with long term anticoagulation
(odds ratio 1.45; 0.93 to 2.27) (table 3). We could not
include all the major bleeding event rates from AFASAK
1 because of insufficient reporting. The recently
published PATAF trial was unusual in reporting a higher
rate of major bleeding in the antiplatelet group
compared with the anticoagulation group (table 2).19
Discussion
The evidence for current clinical practice in long term
anticoagulation for patients with non›rheumatic atrial
fibrillation is not strong. Our search strategy identified
five randomised control trials that had compared long
term anticoagulation with antiplatelet treatment. The
primary annual event rate in the trials varied from
1.7% to 10.6%, reflecting marked clinical heterogeneity
in risk among patients included in the different trials.
Although the trials were set up to examine the effects
of treatment in non›rheumatic atrial fibrillation, most
included a proportion of patients with histories of
myocardial infarction, transient ischaemic attack or
stroke, and heart failure. Such patients would be
expected to contribute to the heterogeneity in the
effects observed because of their higher risk of cardio›
vascular disease. Although cardiovascular risk varied
markedly between the trials, there was no clear relation
between cardiovascular risk and the proportion of
higher risk patients included.
Methodological explanations for trial heterogen›
eity may be more important than previous clinical his›
tories. The randomised control trials were small in
number, two were stopped prematurely, and only one
showed a difference in effect (favouring anticoagula›
tion). This trial was methodologically weaker in design
than the others and may introduce bias in evaluation of
treatment effects. Exclusion of methodologically
weaker studies from a meta›analysis is a recognised
aspect of sensitivity analyses that aim to determine how
much the pooled effect is dependent on one or more
trials with specific characteristics.
The trials showed variation in the degree of blind›
ing of outcome assessment used. When non›fatal
events are counted, failure to blind outcome assessors
to treatment received might bias ascertainment of
stroke events that may be difficult to diagnose. Even
with fatal events knowledge of treatment allocation
may bias attribution of causes of death, although this is
less likely. Consequently, effects of treatment on
mortality are probably more robust that those based
on non›fatal or combined non›fatal and fatal
outcomes.
Despite our findings indicating uncertain benefit
from anticoagulation in terms of reduced risk from
fatal and non›fatal cardiovascular disease in non›
rheumatic atrial fibrillation, it is clear that these trials,
individual and pooled, are underpowered. To detect a
25% superiority of anticoagulation over antiplatelet
treatment with an event rate of 10%, a power of 80%,
and a significance of 5%, trials would require 4920
patients for each treatment group. The trials together
comprised only 3298 patients, which gives the pooled
data only 60% power to detect a difference of this size.
Our search included trials not incorporated in pre›
vious reviews of long term anticoagulation compared
with antiplatelet treatment. These reviews have consist›
ently reported substantial benefits from long term
anticoagulation, and this may be because of failure to
include all the available randomised control trials,2 4 22
the use of composite fatal and non›fatal end points,23 24
and the use of fixed effects models despite significant
heterogeneity.5 23 25 Furthermore, inclusion of the
recently published PATAF trial reduces the effect of
long term anticoagulation in comparison with
antiplatelet treatment.19 The European atrial fibrillation
trial compared warfarin and aspirin in high risk
patients with non›rheumatic atrial fibrillation who had
suffered a recent transient ischaemic attack or minor
stroke.26 The investigators allocated patients eligible for
anticoagulation to receive either warfarin, aspirin, or
placebo and patients who were not eligible for antico›
agulation to aspirin or placebo. The analysis was
confined to pooling both aspirin groups. Conse›
quently, these findings are difficult to interpret.
Benefits
Although the pooled effects on mortality were not sig›
nificant, the confidence intervals were wide. For vascu›
lar deaths, anticoagulation may be up to 37% better
than aspirin or as much as 17% worse. For all the out›
comes considered an effect of anticoagulation as large
as that observed in placebo comparisons (for instance,
a 68% reduction in risk) can be excluded by the pooled
data of this direct comparison. Patients with non›
rheumatic atrial fibrillation may not derive any greater
benefit in terms of reduced death from cardiovascular
disease with long term anticoagulation than with
antiplatelet treatment. The findings conflict with the
findings of randomised control trials that compared
anticoagulation with placebo and antiplatelet with pla›
cebo in patients with non›rheumatic atrial fibrillation.
However, our direct comparison of the two treatments
is the appropriate way to estimate treatment effects and
shows how indirect comparisons tend to overinflate
effect sizes. Our analysis also emphasises the
importance of examining sources of heterogeneity in
meta›analysis and, in particular, trial quality.
Risks
Risk of bleeding is linked to the quality of
anticoagulant control, and the recommended intensity
of anticoagulation for non›rheumatic atrial fibrillation
is an international normalised ratio of 2›3.21 Major
bleeding was 45% more common in patients who
Papers
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received anticoagulation. Bleeding would probably be
more common in routine clinical practice than in trials
in which patient selection has occurred.
Costs
None of the trials considered differences in the costs of
treatment. Outpatient clinics are currently experienc›
ing a 6›24% cumulative increase in referrals for long
term anticoagulation.27 This current demand has
encouraged the uptake of alternative organisational
options such as computer aided dosing,28 near patient
testing,29 and nurse›led services.30 A previous study
estimated that a policy of anticoagulation of all those
eligible for treatment and use of aspirin for the
remainder would be 15 times as expensive as a univer›
sal policy of giving aspirin to everyone with
non›rheumatic atrial fibrillation.31 Given the uncer›
tainty over the greater efficacy of anticoagulation, its
undoubted hazards, and considerations of cost
effectiveness we would strongly favour antiplatelet
drugs in preference to long term anticoagulation.
Thus, the need for the large scale expansion of outpa›
tient anticoagulation services may be less clear.
Further large scale randomised control trials are
needed to compare the costs, benefits, and risk of long
term anticoagulation versus antiplatelet treatment in
patients with non›rheumatic atrial fibrillation. The
effects of different intensities of anticoagulation, with
inclusion of detailed data on adequate therapeutic
control, would need to be explored, as would the effects
of treatment in different cardiovascular disease risk
groups as the absolute benefits of anticoagulant
treatment (if found) will have to be offset against risks
of bleeding. In the meantime, the hospital physician
and general practitioner will have to decide how to
treat patients with non›rheumatic atrial fibrillation.
Firstly, a diagnosis is needed to exclude thyrotoxicosis
and other underlying causes. The patients in this
systematic review included patients from both hospital
clinics and general practice, predominately without
evidence of underlying cardiovascular disease. For
such patients who are already receiving anticoagula›
tion and are happy and stable on this treatment, our
results show that there is little to chose between the two
treatment options, except cost. For new patients, some
doctors may consider it unwise to risk the potential
hazards of major bleeding, with the associated costs to
the patient and the health service, and will chose an
antiplatelet drug. Patient preferences also need to be
taken into account as evidence shows that antiplatelet
treatment is the favoured option in circumstances of
uncertainty of benefit.32 We hope that healthcare
providers will be prepared to randomise patients to
new adequately powered trials to compare the costs,
benefits, and adverse effects of anticoagulation with
antiplatelet treatment.
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Prevalence of overweight and obese children between 1989
and 1998: population based series of cross sectional studies
Peter Bundred, Denise Kitchiner, Iain Buchan
Abstract
Objective To determine trends in weight, height, and
body mass index in children between 1989 and 1998.
Design Retrospective series of cross sectional studies
of routinely collected data.
Setting Primary care in the Wirral Health Authority.
Participants 35 662 infants aged 1›3 months
(representing 88% of live births) and 28 768 children
aged 2.9›4.0 years. 21 582 infants and children
(25.1%) were excluded because of missing or
inaccurate data.
Main outcome measures Weight, height, sex, and age
routinely recorded by health visitors. Height, weight,
and body mass index standardised for age and sex. SD
score > 1.04 for body mass index ( > 85th centile) was
defined as overweight and > 1.64 ( > 95th centile) as
obese. Body mass index was not calculated in infants
as it is difficult to interpret.
Results From 1989 to 1998 there was a highly
significant increasing trend in the proportion of
overweight children (14.7% to 23.6%; P < 0.001) and
obese children (5.4% to 9.2%; P < 0.001). There was
also a highly significant increasing trend in the mean
SD score for weight (0.05 to 0.29; P < 0.001) and body
mass index ( − 0.15 to 0.31; P < 0.001) but not height.
Infants showed a small but significantly increasing
trend in mean SD score for weight ( − 0.17 to − 0.05;
P = 0.005).
Conclusions From 1989 to 1998 there was a highly
significant increase in weight and body mass index in
children under 4 years of age. Routinely collected data
are valuable in identifying anthropometric trends in
populations.
Introduction
The increased number of overweight and obese
children has been highlighted in a cohort study of
British children examined at 24, 49, and 61 months of
age.1 We describe similar findings in a large population
based study, in which data were obtained from
measurements routinely performed by health visitors
as part of the 6 week and preschool assessment. We
examined trends in weight, height, and body mass
index in a defined population between 1989 and 1998.
Participants and methods
Health visitors in the Wirral Health Authority of the
North West region review children regularly, and rou›
tinely collected data are stored on computer. These
data include weight (in grams), height (in centimetres),
date of birth, and date of the examination. We analysed
data from the 6 week and preschool assessments for
the years 1989 to 1998. For the 6 week assessment we
included only infants aged between 28 and 90 days. For
the preschool assessment we included children aged
between 2 years 11 months and 4 years.
The study population consisted of 35 662 infants
and 28 768 children. Records of 21 582 infants and
children (25%) were removed because of missing or
inaccurate data.
We calculated the body mass index (weight
(kg)/height (m)2) for preschool children. This was not
done for infants aged 1 to 3 months as it is difficult to
interpret body mass index at this age. The height,
weight, and body mass index were standardised for age
and sex with the British growth reference charts.2–4 The
resulting standard deviation (SD) scores were used in
all calculations. An SD score of 0 represents the 50th
centile, 1.04 represents the 85th centile, and 1.64 the
95th centile. An SD score > 1.04 for body mass index1 5
was defined as overweight and > 1.64 as obese.
Statistical analysis
StatsDirect software was used for all statistical
calculations.6 We examined trends in weight, height,
The full version of
this paper appears
on the BMJ’s
website. This article
is part of the BMJ’s
trial of open peer
review, and
documentation
relating to this also
appears on the
website
Papers
Editorial by Dietz
University of
Liverpool,
Liverpool L69 3GB
Peter Bundred
reader in primary
care
Royal Liverpool
Children’s NHS
Trust, Liverpool
L12 7AP
Denise Kitchiner
consultant paediatric
cardiologist
West Hertfordshire
Health Authority,
St Albans,
Hertfordshire
AL1 3ER
Iain Buchan
specialist registrar in
public health
Correspondence to:
P Bundred
peterb@liv.ac.uk
BMJ 2001;322:326–8
326 BMJ VOLUME 322 10 FEBRUARY 2001 bmj.com
